News
-
-
-
-
-
-
-
-
PRESS RELEASE
GENFIT : Étape historique franchie avec l'approbation accélérée d'Iqirvo® d’Ipsen dans la Cholangite Biliaire Primitive par la FDA américaine
GENFIT franchit une étape historique avec l'approbation accélérée d'Iqirvo par la FDA américaine pour la Cholangite Biliaire Primitive en partenariat avec Ipsen -
PRESS RELEASE
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
GENFIT achieves historic milestone with U.S. FDA accelerated approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis. Elafibranor tablets approved as first-in-class treatment, marking a significant development in rare liver disease treatment landscape -
PRESS RELEASE
Jolt Health Inc. Terminates Acquisition Agreement and Shifts Focus to AI Opportunities
Jolt Health Inc. terminates acquisition of transdermal delivery technology for chloroquine and hydroxychloroquine, focusing on AI opportunities in healthcare and biotechnology. CEO Gerald Tritt emphasizes value of AI technology and growth initiatives
